Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock

Shock

Volumn 10, Issue 5, 1998, Pages 364-370

  Fourrier, François ^a,b   Jourdain, Mercé ^a   Tournoys, Antoine ^b   Gosset, Philippe ^c   Mangalaboyi, Jacques ^a   Chopin, Claude ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CYTOKINE; FIBRINOGEN; OXYGEN; PROTEIN C;

ANIMAL; ARTICLE; BLOOD; BLOOD CLOTTING; COMPARATIVE STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEMODYNAMICS; METABOLISM; SEPTIC SHOCK; SWINE;

ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION; CYTOKINES; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HEMODYNAMIC PROCESSES; OXYGEN; PROTEIN C; SHOCK, SEPTIC; SWINE;

EID: 0032196478     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199811000-00010     Document Type: Article

References (26)

1. Bauer KA, Rosenberg RD: Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol 28:10-18, 1991.
2. Büller HR, Ten Cate JW: Acquired antithrombin III deficiency, laboratory diagnosis, incidence, clinical implications, treatment with antithrombin III concentrate. In Rosenberg RD (ed): Role of Antithrombin III in Coagulation Disorders: State of the Art Review. Am J Med 87(suppl. 3B):44s-48s, 1989.
3. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K: Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 270:L921-L930, 1996.
4. Gray E, Thomas S, Mistry Y, Poole S: Inhibition of tissue factor, cytokine release. Haemostasis 26(suppl 1):92-95, 1996.
5. Emerson TE, Fournel MA, Redens TB, Taylor FB Jr: Efficacy of antithrombin III supplementation in animal models of fulminant E. coli endotoxemia or bacteremia. In Rosenberg RD (ed): Role of Antithrombin III in Coagulation Disorders: State of the Art Review. Am J Med 87(suppl. 3B): 27s-33s, 1989.
6. Fourrier F, Chopin C, Goudemand J, et al.: Septic shock, multiple organ failure, disseminated intravascular coagulation: Compared patterns of antithrombin III, PC and protein S deficiencies. Chest 101:816-882, 1992.
7. Seitz R, Wolf M, Egbring R, et al.: Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections. Eur J Haematol 38:231-240, 1987.
8. Jordan RE, Kilpatrick J, Nelson RM: Heparin promotes the inactivation of antithrombin by elastase. Science 237:777-775, 1987.
9. Taylor FB Jr, Emerson TE, Jordan R, Chang AK, Blick KE: Antithrombin III prevents the lethal effects of E. coli infusion in the baboons. Circ Shock 26:227-235, 1988.
10. Redens TB, Emerson TE: Antithrombin III treatment limits disseminated intra-vascular coagulation in endotoxemia. Circ Shock 28:49-58, 1989.
11. Dickneite G, Pâques EP: Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae induced sepsis. Thrombos Haemost 69:98-102, 1993.
12. Redens TB, Leach WJ, Bogdanoff DA, Emerson TE: Synergistic protection from lung damage by combining antithrombin III and a-1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model. Circ Shock 26:15-26, 1988.
13. Fourrier F, Lestavel P, Chopin C, et al.: Meningococcemia, purpura fulminans in adults: Acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 16:1-4, 1990.
14. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J: Double blind placebo-controlled study of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888, 1993.
15. Lamy M, Eisele B, Keinecke HO, Delvos U, Thijs LG: Antithrombin III in patients with severe sepsis: A randomized placebo-controlled double blind multicenter trial. In Proceedings of the 9th European Congress on Intensive Care Medicine. Bologna, Italy: Monduzzi Editore, pp 385-390, 1996.
16. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M: Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 8:328-334, 1997.
17. Esmon CT: The protein C pathway: New insights. Thromb Haemost 78:70-74, 1997.
18. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic, lethal effects of E. coli in the baboon. J Clin Invest 79:918-924, 1987.
19. Smith OP, White B, Vaughan D, et al.: Use of protein C concentrate, heparin, haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 350:1590-1593, 1997.
20. 2-terminal amino acid sequence of a T cell derived lymphokine with growth activity for B cell hybridomas. Proc Natl Acad Sci USA 83:9679-9685, 1986.
21. Woodman RC, Ostrovsky L, Teoh D, Payne D, Poon MC, Kubes P: Antithrombin, ischemia-reperfusion. Blood Coagul Fibrinolysis 9(suppl 2):S7-S15, 1998.
22. Dickneite G: The anticoagulant, antiinflammatory effect of antithrombin III in experimental sepsis. Intensive Care Med 23(suppl 1):S58, 1997.
23. Roback MG, Stack AM, Thompson C, Brugnara C, Schwarz HP, Saladino RA: Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock 9:138-142, 1998.
24. Murakami K, Okajima K, Uchiba M, et al.: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272:L197-L202, 1997.
25. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW: Selective inhibitory effect of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, INFγ, or phorbol ester. J Immunol 153:3664-3668, 1994.
26. Maruyama Y, Maruyama I, Soejima Y: Thrombin receptor agonist peptide decreases thrombomodulin activity in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 199:1262-1269, 1994.